

**RECEIVED  
CENTRAL FAX CENTER**

**SEP 09 2010**

Application No. 10/807,897 - - - - 2

**AMENDMENTS TO THE CLAIMS**

Claim 1 (currently amended). An oral DNA vaccine suitable for eliciting an immune response against cancer cells in a patient comprising a DNA construct operably encoding at least one survivin protein and one CCL21 cytokine in a pharmaceutically acceptable carrier; wherein the DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut, wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to the patient, and the attenuated *Salmonella typhimurium* vector comprises [[and]] an aroA, dam *Salmonella typhimurium* strain.

Claims 2-25 (canceled).

Claim 26 (previously presented). The DNA vaccine of claim 1 wherein the DNA construct operably encoding the survivin protein comprises SEQ ID NO: 3.

Claim 27 (canceled).

Claim 28 (previously presented). The DNA vaccine of claim 1 wherein the DNA construct operably encoding the CCL21 cytokine comprises SEQ ID NO: 7.

Claims 29-52 (canceled).

Claim 53 (previously presented). The DNA vaccine of claim 1 wherein the DNA construct operably encoding the survivin protein comprises SEQ ID NO: 3, and wherein the DNA construct operably encoding the CCL21 cytokine comprises SEQ ID NO: 7.